Given Imaging's M2A to be Reimbursed by Blue Shield of California

4 February 2003 - ATLANTA, GA -- Given Imaging (NASDAQ:GIVN) announced today that Blue Shield of California has established a reimbursement coverage policy for the use of capsule endoscopy in obscure digestive tract bleeding suspected to be of small bowel origin.

"We are pleased that respected third-party payers like Blue Shield of California recognize the value that our M2A capsule endoscopy procedure holds for their members," said Gavriel D. Meron, President and CEO of Given Imaging. "The growing momentum in reimbursement coverage achieved over the last year is encouraging and we look forward to being able to help more physicians offer this patient-friendly and effective diagnostic procedure to patients who need it."

Blue Shield of California has approximately 2.6 million members which means that now almost 50 million Americans have reimbursable access to Given Imaging’s capsule endoscopy.

About Blue Shield of California

Founded in 1939, Blue Shield of California is one of the state's leading healthcare companies. Headquartered in San Francisco, the not-for-profit corporation has more than 2.6 million members, 4,400 employees and more than 20 office locations throughout California. For more information on Blue Shield, visit the company's Web site at www.mylifepath.com.

For additional information please see Given Imaging's reimbursement fact sheet at http://www.givenimaging.com/usa/reimbursement.asp Editor's Note: This link is no longer active.

This press release contains forward-looking statements about Given Imaging, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03